pirenzepine has been researched along with Hyperglycemia in 28 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the clinical characteristics of hyperglycemia in patients treated with olanzapine." | 8.81 | Olanzapine-associated diabetes mellitus. ( Doraiswamy, PM; Koller, EA, 2002) |
| "The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 7.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
| "We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history." | 7.71 | Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. ( Gibson, B; Kang, N; Malyuk, R; Procyshyn, RM, 2002) |
| "Olanzapine has been associated with insulin resistance and new-onset diabetes mellitus." | 6.41 | Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. ( Doraiswamy, PM; McLendon, BM; Seaburg, HL, 2001) |
| "Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents." | 5.31 | Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "To explore the clinical characteristics of hyperglycemia in patients treated with olanzapine." | 4.81 | Olanzapine-associated diabetes mellitus. ( Doraiswamy, PM; Koller, EA, 2002) |
| "The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 3.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
| "To examine quantitatively the association between glucose intolerance including diabetes mellitus and the use of the atypical antipsychotics clozapine, olanzapine or risperidone, and to identify possible risk factors for the development of glucose intolerance during treatment with these drugs." | 3.71 | Glucose intolerance with atypical antipsychotics. ( Hägg, S; Hedenmalm, K; Mortimer, O; Spigset, O; Ståhl, M, 2002) |
| "We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history." | 3.71 | Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. ( Gibson, B; Kang, N; Malyuk, R; Procyshyn, RM, 2002) |
| "However, hyperglycemia (especially postprandial hyperglycemia) and hypoglicemia continue to be problematic in the management of type 1 diabetes." | 2.44 | [Adjunctive therapies to glycaemic control of type 1 diabetes mellitus]. ( Gabbay, Mde A, 2008) |
| "Olanzapine has been associated with insulin resistance and new-onset diabetes mellitus." | 2.41 | Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. ( Doraiswamy, PM; McLendon, BM; Seaburg, HL, 2001) |
| "Olanzapine is an atypical antipsychotic that is becoming more widely used in children and adolescents." | 1.31 | Hyperglycemia and hypertriglyceridemia secondary to olanzapine. ( Domon, SE; Webber, JC, 2001) |
| "A 45-year-old man with well-controlled type 2 diabetes mellitus experienced an abrupt worsening of his diabetes after 3 years of olanzapine therapy His hemoglobin A1c (HbA1c) level rose from a baseline of 5." | 1.31 | Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. ( Bechara, CI; Goldman-Levine, JD, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 22 (78.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koller, EA | 1 |
| Doraiswamy, PM | 3 |
| Meatherall, R | 1 |
| Younes, J | 1 |
| Spivak, B | 1 |
| Alamy, SS | 1 |
| Jarskog, LF | 1 |
| Sheitman, BB | 1 |
| Lieberman, JA | 2 |
| Hedenmalm, K | 1 |
| Hägg, S | 1 |
| Ståhl, M | 1 |
| Mortimer, O | 1 |
| Spigset, O | 1 |
| Azriel Mira, S | 1 |
| Lindenmayer, JP | 3 |
| Czobor, P | 1 |
| Volavka, J | 1 |
| Citrome, L | 1 |
| Sheitman, B | 1 |
| McEvoy, JP | 1 |
| Cooper, TB | 1 |
| Chakos, M | 1 |
| Gupta, S | 1 |
| Bloch, Y | 1 |
| Vardi, O | 1 |
| Mendlovic, S | 1 |
| Levkovitz, Y | 1 |
| Gothelf, D | 1 |
| Ratzoni, G | 1 |
| Landry, P | 1 |
| Benaliouad, F | 1 |
| Gabbay, Mde A | 1 |
| Ter Braak, GI | 1 |
| Fertig, MK | 1 |
| Brooks, VG | 1 |
| Shelton, PS | 1 |
| English, CW | 1 |
| Ober, SK | 1 |
| Hudak, R | 1 |
| Rusterholtz, A | 1 |
| Von Hayek, D | 1 |
| Hüttl, V | 1 |
| Reiss, J | 1 |
| Schweiger, HD | 1 |
| Füessl, HS | 1 |
| Mir, S | 1 |
| Taylor, D | 1 |
| Smith, RC | 2 |
| Singh, A | 1 |
| Parker, B | 1 |
| Chou, E | 1 |
| Kotsaftis, A | 1 |
| Kropp, S | 1 |
| Emrich, HM | 1 |
| Bleich, S | 1 |
| Degner, D | 1 |
| Nathan, AM | 1 |
| Domon, SE | 1 |
| Webber, JC | 1 |
| Bechara, CI | 1 |
| Goldman-Levine, JD | 1 |
| Seaburg, HL | 1 |
| McLendon, BM | 1 |
| Koller, E | 1 |
| Malozowski, S | 1 |
| Ramankutty, G | 1 |
| Riccitelli, G | 1 |
| Baker, N | 1 |
| Malyuk, R | 1 |
| Gibson, B | 1 |
| Procyshyn, RM | 1 |
| Kang, N | 1 |
| Sowell, MO | 1 |
| Mukhopadhyay, N | 1 |
| Cavazzoni, P | 1 |
| Shankar, S | 1 |
| Steinberg, HO | 1 |
| Breier, A | 1 |
| Beasley, CM | 1 |
| Dananberg, J | 1 |
| Mimura, A | 1 |
| Kageyama, S | 1 |
| Itoh, K | 1 |
| Miura, J | 1 |
| Kurata, H | 1 |
| Yokoyama, J | 1 |
| Ikeda, Y | 1 |
| Atiea, JA | 1 |
| Creagh, F | 1 |
| Page, M | 1 |
| Owens, DR | 1 |
| Scanlon, MF | 1 |
| Peters, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
6 reviews available for pirenzepine and Hyperglycemia
| Article | Year |
|---|---|
Olanzapine-associated diabetes mellitus.
Topics: Benzodiazepines; Diabetes Mellitus; Humans; Hyperglycemia; Olanzapine; Pirenzepine; Retrospective St | 2002 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].
Topics: Acarbose; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Gastrointest | 2008 |
Atypical antipsychotics and hyperglycaemia.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dia | 2001 |
Hyperglycemia associated with the use of atypical antipsychotics.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; | 2001 |
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetic Ketoacidosis; Humans; Hyperglycemia; Ketone B | 2001 |
2 trials available for pirenzepine and Hyperglycemia
| Article | Year |
|---|---|
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Glucose Clamp Technique; Huma | 2002 |
20 other studies available for pirenzepine and Hyperglycemia
| Article | Year |
|---|---|
Fatality from olanzapine induced hyperglycemia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Dehydration; Diabetes Complicati | 2002 |
Ziprasidone alternative for olanzapine-induced hyperglycemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Male | 2002 |
Glucose intolerance with atypical antipsychotics.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bayes Theorem; Benzodiazepines; Chlor | 2002 |
[Uncontrolled hyperglycemia with ketosis associated with olanzapine therapy].
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Hyperglycemia; Ketosis; Male; Middle Aged; Olanzapine | 2002 |
Hyperglycemia from olanzapine treatment in adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; | 2003 |
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?
Topics: Antipsychotic Agents; Benzodiazepines; Cholesterol; Clozapine; Humans; Hyperglycemia; Hyperlipidemia | 2003 |
[The hyperglycemic dehydration syndrome].
Topics: Adult; Antidepressive Agents; Benzodiazepines; Clomipramine; Dehydration; Depressive Disorder; Diabe | 1998 |
Hyperglycemia associated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1998 |
Hyperglycemia and olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Comorbidity; Depressive Disorder; Diabetes Mel | 1999 |
[Hyperglycemia and ketoacidosis associated with olanzapine].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetic Ketoacidosis; Fatal Outcome; Female; Humans; | 1999 |
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperglycemia; Ma | 2001 |
Olanzapine-related hyperglycemia in a nondiabetic woman.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Olanzapine; Pirenzepine | 2001 |
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Humans; Hyperglycemia; Hypertriglyceridemia; Male | 2001 |
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.
Topics: Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hyperglycemi | 2001 |
Atypical antipsychotic drugs and hyperglycemia in adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Hyperglycemia; Olanzapine; Pir | 2001 |
Olanzapine-induced destabilization of diabetes in the absence of weight gain.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Complications; Diabetes | 2002 |
Weight gain and hyperglycaemia associated with olanzapine.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Olanzapine; Pirenz | 2002 |
Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.
Topics: Antipsychotic Agents; Benzodiazepines; Female; Humans; Hyperglycemia; Middle Aged; Neuroleptic Malig | 2002 |
[Role of growth hormone in the pathogenesis of dawn phenomenon in IDDM].
Topics: Adult; Circadian Rhythm; Diabetes Mellitus, Type 1; Growth Hormone; Humans; Hyperglycemia; Insulin I | 1992 |
Early morning hyperglycemia in insulin-dependent diabetes: acute and sustained effects of cholinergic blockade.
Topics: Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Glucagon; Growth Hormone; Humans; | 1989 |